Laparoscopic band-separated mini-gastric bypass

Comparison of laparoscopic band-separated mini-gastric bypass and linear cutter stapler-separated mini-gastric bypass: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN56106651

Enrollment

Registered

2016-01-06

Start date

2015-07-20

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid obesity Nutritional, Metabolic, Endocrine

Interventions

Participants are randomly allocated have one of two possible surgeries: 1. Laparoscopic band-separated mini-gastric bypass: An adjustable low pressure gastric band was introduced in th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Obese patients: 1. aged between 18 and 60 2. with American Society of Anesthesiologists (ASA) physical status of I or II 3. BMI = 35

Exclusion criteria

Exclusion criteria: Obese patients with BMI = 60 kg/m2.

Design outcomes

Primary

Measure	Time frame
1. Weight loss, measured by body weight in kg (BMI – body mass index kg/m 2) and waist circumference before and after surgery and also the percentage of excess weight loss (%EWL) (at 6 months and then 12 months after surgery) 2. Changes in co-morbidities by evaluation of symptoms: diabetes improved or resolved in % of patients, hyperlipidemia improved in %, hypertension improved or resolved in %, and obstructive sleep apnea improved or resolved in % of patients 3. Quality of life, measured by the quality of life questionnaire the Moorehead-Ardelt Quality of Life Questionnaire II Follow-up for all treatment arms: 1, 3, 6, 12 months after the surgery	—

Measure

Time frame

1. Weight loss, measured by body weight in kg (BMI – body mass index kg/m 2) and waist circumference before and after surgery and also the percentage of excess weight loss (%EWL) (at 6 months and then 12 months after surgery) 2. Changes in co-morbidities by evaluation of symptoms: diabetes improved or resolved in % of patients, hyperlipidemia improved in %, hypertension improved or resolved in %, and obstructive sleep apnea improved or resolved in % of patients 3. Quality of life, measured by the quality of life questionnaire the Moorehead-Ardelt Quality of Life Questionnaire II Follow-up for all treatment arms: 1, 3, 6, 12 months after the surgery

—

Secondary

Measure	Time frame
Postoperative morbidity	—

Countries

Kazakhstan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 1, 2026